Article
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Journal of clinical pharmacology - 1 Feb 2017
Zhu Li, Brüggemann Roger J, Uy Jonathan, Colbers Angela, Hruska Matthew W, Chung Ellen, Sims Karen, Vakkalagadda Blisse, Xu Xiaohui, van Schaik Ron H N, Burger David M, Bertz Richard J
Abstract excerpt
Voriconazole, a broad-spectrum triazole antifungal agent, is metabolized by cytochrome P450 (CYP) 2C19 and, to a lesser extent, by CYP3A. Genetic polymorphism of CYP2C19 not only plays a prominent role in its disposition but may also influence potential drug interactions with CYP450 modulators such as ritonavir. This study assessed 2-way drug interactions of voriconazole added on to ritonavir-boosted atazanavir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.